Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its first and only approved product, Rezdiffra (resmetirom), is a once-daily oral, liver-directed… From the company’s description.
Over the twelve months to Sep 30, 2026, Madrigal Pharmaceuticals, Inc. reported revenue of $1.43B, up 92.8% from a year earlier, and a net loss of $155.46M. Its operating margin was −10.7%, and operations used $157.01M in cash. In fiscal 2025, it reported revenue of $958.40M, up 432.1% from fiscal 2024, and a net loss of $288.28M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Madrigal Pharmaceuticals, Inc. does
In the company’s own words
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its first and only approved product, Rezdiffra (resmetirom), is a once-daily oral, liver-directed thyroid hormone receptor beta agonist for adults with noncirrhotic MASH and moderate to advanced liver fibrosis. Approved in the United States and conditionally authorized in the European Union, Rezdiffra launched in the United States in 2024 and Germany in 2025. Madrigal is also developing a MASH pipeline that includes MGL-2086, an oral GLP-1 receptor agonist; ervogastat, an oral DGAT-2 inhibitor; and six preclinical small interfering RNA programs. The company holds worldwide rights to resmetirom under a license from Roche and licenses its pipeline candidates from other companies. Madrigal generated $958.4 million in Rezdiffra product revenue for fiscal 2025. Its website is www.madrigalpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WEST CONSHOHOCKEN, PA
- Fiscal year end
- December
- CIK
- 1157601
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Madrigal Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Madrigal Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Madrigal Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Madrigal Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Madrigal Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”